Epilepsy: A Multifaced Spectrum Disorder

The paper frames epilepsy as a heterogeneous brain disorder that extends beyond recurrent seizures to include broad psychosocial consequences and a complex spectrum of cognitive, psychiatric, and medical comorbidities. It emphasizes the importance of neuropsychological assessment for understanding clinical symptoms, psychiatric comorbidities, pharmacotherapy effects, social functioning, and cognitive impairments, all of which are critical for accurate diagnosis and tailored neurorehabilitation. The work stresses a holistic, patient-centered approach that integrates clinical, cognitive, affective, psychosocial, and neurobiological factors to improve management and outcomes, including in surgical candidacy evaluations.

The article references key frameworks and evidence: (1) ILAE’s practical clinical definition of epilepsy (2014) highlighting psychosocial consequences; (2) the 2017 ILAE classification recognizing comorbidities as essential to diagnosis; (3) WHO’s 2019 global report underscoring psychiatric comorbidities and the need for their recognition and treatment. It summarizes evidence that neuropsychological evaluations in epilepsy should cover domains including intellect/adaptive functioning, attention, memory/learning, language, visuospatial skills, executive functions, sensorimotor skills, academic abilities, emotional-behavioral functioning, and quality of life. Reviews indicate high prevalence of psychiatric comorbidities (notably mood and anxiety disorders), associations between psychiatric comorbidity and increased mortality, and elevated rates of systemic medical comorbidities (endocrine/metabolic, respiratory, urogenital, cardiovascular). In children and adolescents, there is frequent co-occurrence with neurodevelopmental disorders (ASD, ADHD, learning disorders), consistent with a shared genetic susceptibility. Emerging perspectives advocate network-based precision taxonomies and precision medicine approaches to address the neurobehavioral comorbidities of epilepsy.

• Epilepsy affects about 50 million people worldwide and presents with diverse etiologies, seizure types, severities, and impacts.
• Epilepsy encompasses more than seizures, involving psychosocial consequences and a broad spectrum of psychiatric and medical comorbidities.
• Reported psychiatric comorbidity prevalence in epilepsy: mood disorders ~35%; anxiety disorders ~25.6%; psychotic disorders ~5.7%; substance abuse ~8%; overall suicide risk ~9%.
• Individuals with epilepsy have higher mortality risk than the general population; those with psychiatric comorbidities have a 1.4-fold higher mortality than those with epilepsy without psychiatric illness (adjusted for age and sex).
• Non-psychiatric comorbidities (endocrine/metabolic, respiratory, urogenital, cardiovascular) can be up to eight times more frequent in epilepsy, contributing substantially to disease burden.
• Neurodevelopmental comorbidities (ASD, ADHD, learning challenges) commonly co-occur in youth with epilepsy, likely due to shared genetic susceptibility.
• Neuropsychological assessment is central for profiling cognitive-behavioral functioning, guiding diagnosis, rehabilitation, and surgical planning/prognosis in drug-resistant cases.
• Psychosocial factors (stressful events, awareness, adaptation, perceived support, stigma) significantly shape psychopathology and outcomes in epilepsy.

The findings support reconceptualizing epilepsy as a multifaceted spectrum disorder in which seizures are one component of a broader clinical phenotype that includes cognitive, psychiatric, and systemic medical comorbidities. Recognizing these dimensions informs comprehensive care: systematic neuropsychological evaluations aid in understanding individual profiles, localizing dysfunction in surgical candidates, and anticipating outcomes. High rates of psychiatric and medical comorbidities underscore the need for routine screening and integrated management, as psychiatric conditions worsen quality of life and increase mortality risk. In pediatric populations, overlap with neurodevelopmental disorders suggests shared mechanisms, reinforcing the value of genetic and neurobiological perspectives. Given limited evidence for antiepileptic drugs’ effects on psychiatric comorbidities, psychotherapeutic interventions and careful avoidance of polypharmacy are recommended. Overall, integrating clinical, cognitive, psychosocial, and biological factors aligns with precision, patient-centered care and may improve long-term outcomes.

Epilepsy should be approached as a multifaceted spectrum disorder that necessitates holistic, individualized care. Comprehensive neuropsychological assessment, recognition and management of psychiatric and medical comorbidities, and consideration of neurodevelopmental overlaps are essential. The authors advocate a new paradigm emphasizing neurobiological diversity, genomic influences, and resilience factors, aiming toward precision medicine that focuses on the individual patient to optimize outcomes.